Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

Autres documents

F1308

Sigma-Aldrich

Fosinopril sodium

≥98% (HPLC), powder

Synonyme(s) :

(2S,4S)-4-Cyclohexyl-1-(2-{[2-methyl-1-(propanoyloxy)propoxy](4-phenylbutyl)phosphoryl}acetyl)pyrrolidine-2-carboxylic acid, Acecor, Eosinopril, Fosinopril, Monopril, SQ 28555, Secorvas, Staril

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C30H45NO7P · Na
Numéro CAS:
88889-14-9
Poids moléculaire :
585.64
Numéro MDL:
MFCD23704184
Code UNSPSC :
12352200
ID de substance PubChem :
329799677
Nomenclature NACRES :
NA.77

Niveau de qualité

100

Pureté

≥98% (HPLC)

Forme

powder

Conditions de stockage

desiccated

Couleur

white to off-white

Solubilité

H2O: >20 mg/mL

Auteur

Bristol-Myers Squibb

Température de stockage

−20°C

Chaîne SMILES 

O=C([O-])[C@H]1N(C(CP(CCCCC2=CC=CC=C2)(O[C@@H](C(C)C)OC(CC)=O)=O)=O)C[C@H](C3CCCCC3)C1.[Na+]

InChI

1S/C30H46NO7P.Na/c1-4-28(33)37-30(22(2)3)38-39(36,18-12-11-15-23-13-7-5-8-14-23)21-27(32)31-20-25(19-26(31)29(34)35)24-16-9-6-10-17-24;/h5,7-8,13-14,22,24-26,30H,4,6,9-12,15-21H2,1-3H3,(H,34,35);/q;+1/p-1/t25-,26+,30+,39?;/m1./s1

Clé InChI

TVTJZMHAIQQZTL-TXDYNIFHSA-M

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

Fosinopril lowers blood pressure and functions as an antihypertensive agent. It is an ester prodrug. Fosinopril is metabolised by the liver and excreted from the body by liver and kidney. It is used to treat heart failure.

Actions biochimiques/physiologiques

Fosinopril is an angiotensin converting enzyme (ACE) inhibitor. Fosinopril is also known to inhibit the activity of the peptide transporter PEPT2.

Caractéristiques et avantages

This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Bristol-Myers Squibb. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictogrammes

Exclamation markHealth hazard
GHS07,GHS08

Mention d'avertissement

Warning

Mentions de danger

H319 - H361d

Classification des risques

Eye Irrit. 2 - Repr. 2

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Abhishek S Chitnis et al.
Research in social & administrative pharmacy : RSAP, 8(2), 145-156 (2011-04-23)
Heart failure is a major and growing public health problem in United States. There is a substantial evidence about efficacy of angiotensin-converting enzyme inhibitors (ACEIs) in heart failure (HF); however, there is no conclusive evidence on the relative effectiveness of
Lakhan Kma et al.
Journal of radiation research, 53(1), 10-17 (2012-02-04)
Our long-term goal is to use angiotensin converting enzyme (ACE) inhibitors to mitigate the increase in lung collagen synthesis that is induced by irradiation to the lung, which could result from accidental exposure or radiological terrorism. Rats (WAG/RijCmcr) were given
Giuseppe Mancia et al.
BMJ (Clinical research ed.), 340, c1197-c1197 (2010-03-27)
To investigate the possibility that statins reduce blood pressure as well as cholesterol concentrations through clinic and 24 hour ambulatory blood pressure monitoring. Randomised placebo controlled double blind trial. 13 hospitals in Italy 508 patients with mild hypertension and hypercholesterolaemia
Tie Zhao et al.
Journal of pharmaceutical and biomedical analysis, 60, 32-43 (2011-12-14)
The pathological development of diabetic kidney disease (DKD) might involve metabolic perturbations in kidney tissue. The present study was designed to detect the systematic alterations of renal cortex metabolites thereby exploring the related mechanisms of DKD development and fosinopril treatment.
Current Cardiovascular Drugs (2005)
Afficher tous les articles scientifiques apparentés

Articles

Angiotensin Receptors

We offer many products related to angiotensin receptors for your research needs.

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique